|
Laboratory Study in Gastric Nitrosamine Formation
|
|
1
|
135
|
October 24, 2024
|
|
Software for prediction of NDSRI generation
|
|
5
|
513
|
October 24, 2024
|
|
N-Nitroso duloxetine methods from SwissMedic and Taiwan FDA
|
|
0
|
108
|
October 24, 2024
|
|
Become a USP Expert Volunteer
|
|
2
|
520
|
October 24, 2024
|
|
Nationwide recall of duloxetine
|
|
0
|
227
|
October 23, 2024
|
|
AAPS PharmSci360 -Nitrosamines
|
|
13
|
422
|
October 22, 2024
|
|
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test -Pub
|
|
16
|
467
|
October 21, 2024
|
|
Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets -Pub
|
|
7
|
1111
|
October 19, 2024
|
|
Managing Nitrite Impurities: A Supplier-Manufacturer Approach to Mitigate Nitrosamine Risk
|
|
2
|
488
|
October 18, 2024
|
|
🇦🇺 TGA Australia Published Acceptable intakes for Nitrosamines
|
|
3
|
1210
|
October 17, 2024
|
|
FDA Acceptable intake limit for multiple nitrosamines in one drug product -Calculation
|
|
1
|
356
|
October 16, 2024
|
|
"Ribolaris" clinical trial has been partially suspended due to nitrosamine impurities in ribociclib batches
|
|
1
|
158
|
October 16, 2024
|
|
LC-MS: Practical method for analyzing NDSRIs with single quadrupole
|
|
2
|
202
|
October 16, 2024
|
|
Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets -Pub FDA
|
|
2
|
150
|
October 15, 2024
|
|
Reactivities of N-Nitrosamines against Common Reagents and Reaction Conditions -Pub
|
|
2
|
292
|
October 15, 2024
|
|
Selection of Solvent and Positive Control Concentration for Enhanced Ames Test Conditions for N-Nitrosamine Compounds -Pub
|
|
0
|
130
|
October 11, 2024
|
|
Selection of Solvent and Positive Control Concentration for Enhanced AMES Test -Pub
|
|
0
|
96
|
October 14, 2024
|
|
Oral Liquid Formulations
|
|
4
|
175
|
October 14, 2024
|
|
西格列汀相关亚硝胺杂质(nttp)的ai值 - AI value of sitagliptin related impurity
|
|
2
|
210
|
October 12, 2024
|
|
N-Nitrosamines: bacterial mutagenesis and in vitro metabolism -A MUST READ
|
|
9
|
766
|
October 10, 2024
|
|
Dynamics of Nitroso-STG-19 entering the blood circulation
|
|
1
|
120
|
October 10, 2024
|
|
🖥 Berkeley Madonna Software for Nitrosation Kinetic Calculations
|
|
5
|
749
|
October 10, 2024
|
|
🇸🇦 Saudi FDA requesting Nitrosamines Risk Assessments
|
|
5
|
1638
|
October 9, 2024
|
|
Nitrite Scavengers in Solution and Solid State
|
|
16
|
3349
|
October 7, 2024
|
|
Limits of those Nitrosamines deleted from Table 1 in the guidance
|
|
2
|
390
|
October 4, 2024
|
|
Chloride suppression in nitrite IC analysis
|
|
1
|
140
|
October 3, 2024
|
|
CROs for TGR mutation assay
|
|
8
|
294
|
October 2, 2024
|
|
Aptar’s N-Sorb Nitrosamine Mitigation Solution Accepted to US FDA’s Emerging Technology Program
|
|
6
|
416
|
October 2, 2024
|
|
Case Studies for CPCA Scoring
|
|
18
|
4061
|
September 30, 2024
|
|
🖩 CPCA Calculation Tool (excel-based) -Updated
|
|
87
|
10805
|
September 27, 2024
|